TRAF3IP2 Antibody

NF-kB (nuclear factor kB) is sequestered in the cytoplasm by IkB family of inhibitory proteins that mask the nuclear localization signal of NF-kB thereby preventing translocation of NF-kB to the nucleus (1). External stimuli such as tumor necrosis factor or other cytokines, such as IL-1 results in phosphorylation and degradation of IkB releasing NF-kB dimers. NF-kB dimer subsequently translocates to the nucleus and activates target genes (2). Recently, Li et al. (3) have isolated a cDNA coding for a protein named Act1 (NF- B activator 1). Act1/CIKS cDNA codes for a protein containing 574 aa with a predicated molecular mass of 60 kDa. Act1/CIKS protein contains a helix-loop-helix domain in its N-terminal portion and a coiled-coil structure at the C terminus. Act1 lacks any catalytic domain, however, it activates IKK through the helix-loop-helix domain. The activation of NF- B by Act1 appears to be through the NIK-IKK complex, because a NIK dominant-negative mutant protein inhibited Act1-induced NF- B activation. IL-1 responsive pathway is also necessary for Act1 function. Act1 mRNA is expressed in a variety of tissues, with high level in thymus, kidney and placenta; moderate level in heart, skeletal muscle, colon, liver, lung and small intestine; and at a very low level in brain, spleen, and peripheral blood leukocytes.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: IP, WB.

Showing Publications 1 - 10 of 13. Show All 13 Publications. Collapse Publications.

Publications using NB100-56740	Applications	Species
Das NA, Carpenter AJ, Belenchia A, et al. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition Cell. Signal. 2019-12-17 [PMID: 31862399] (WB, Human)	WB	Human
Das NA, Carpenter AJ, Yashida T et al. TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart J Mol Cell Cardiol. 2018-07-05 [PMID: 29981796] (WB, Mouse)	WB	Mouse
Padilla J, Carpenter A, Das ND et al. TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2017-09-29 [PMID: 28971844] (WB)	WB
Yariswamy M, Yoshida T, Valente AJ et al. Cardiac-Restricted Overexpression of TRAF3 Interacting Protein 2 (TRAF3IP2) Results in Spontaneous Development of Myocardial Hypertrophy, Fibrosis and Dysfunction. J Biol Chem. [PMID: 27466370] (WB, Mouse)	WB	Mouse
Mummidi S, Das NA, Carpenter AJ et al. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone + salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol. 2017-09-01 [PMID: 27423273] (WB, Mouse)	WB	Mouse
Sakamuri SS, Valente AJ, Siddesha JM et al. TRAF3IP2 mediates aldosterone/salt-induced cardiac hypertrophy and fibrosis. Mol. Cell. Endocrinol. 2016-04-01 [PMID: 27040306] (WB, Mouse)	WB	Mouse
Somanna NK, Yariswamy M, Garagliano JM et al. Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2 Cell. Signal. 2015-07-04 [PMID: 26148936] (WB, Mouse)	WB	Mouse
Valente AJ, Irimpen AM, Siebenlist U et al. OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators Free Radic Biol Med 2014-02-25 [PMID: 24561578] (WB, IP, Human)	WB, IP	Human
Valente AJ, Yoshida T, Izadpanah R et al. Interleukin-18 enhances IL-18R/Nox1 binding, and mediates TRAF3IP2-dependent smooth muscle cell migration. Inhibition by simvastatin. Cell Signal. 2013-06-01 [PMID: 23541442]
Valente AJ, Yoshida T, Clark RA et al. Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling. Free Radic Biol Med. 2013-07-01 [PMID: 23453926]
Tovell H SGK3 activity and regulation in PI3K-Akt pathway inhibitor resistance in breast cancer Thesis 2020-01-01 (WB, Human)	WB	Human
Sukhanov S, Higashi Y, Yoshida T et al. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion J Virol 2020-11-04 [PMID: 33160017]
Dashek R, Higashi Y, Das N et al. Effects of Empagliflozin on Intermittent Hypoxia-Induced TRAF3IP2-Dependent Human Aortic Smooth Muscle Cell Proliferation Medical Research Archives 2022-11-02 (WB, Human)	WB	Human
Show All 13 Publications. Collapse Publications.

Array NB100-56740

• TRAF3IP2 Antibodies
• TRAF3IP2 Lysate
• TRAF3IP2 Proteins